甲托雷克萨和生物疗法与类风湿性关节炎的脂肪肝无关 - - 一项横截面研究
Tatjana Zekić1, Filip Blažić2, Nataša Katalinić3
1Faculty of Medicine, Department of rheumatology and clinical immunology, University of Rijeka, Clinical Hospital Center Rijeka, Rijeka, Croatia. zekic.tatjana79@gmail.com.
Rheumatology international
|September 24, 2025
概括
类风湿性关节炎患者患有非酒精性脂肪性肝病 (NAFLD) 的患病率很高,通常与代谢综合征有关. 虽然甲状腺素和TNFi治疗没有影响,但IL-6抑制剂可以减少RA患者的NAFLD.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 影响约30%的类风湿性关节炎 (RA) 患者.
- 关节炎治疗和NAFLD之间的相互作用需要临床澄清.
研究的目的:
- 评估各种疾病修饰性抗风湿药物 (DMARD) 对RA患者NAFLD患病率和肝纤维化的影响.
- 分析NAFLD,肝硬度和RA的临床参数之间的关系.
主要方法:
- 该研究包括170名RA患者,他们被评估为NAFLD (受控减弱参数[CAP]≥275dB/m) 和肝纤维化 (肝硬度测量[LSM]>8kPa).
- 患者按使用甲状腺素 (MTX) 和使用生物制剂 (瘤缩因子抑制剂 [TNFi],干白素-6 [IL-6] 抑制剂) 分类.
主要成果:
- NAFLD的患病率为36%,与代谢综合征的组成部分相关,如BMI,腰围和肝酶升高.
- 在治疗组或MTX累积剂量之间没有发现NAFLD患病率的显著差异.
- TNFi治疗持续时间与NAFLD或纤维化无关,但IL-6抑制剂持续时间与NAFLD呈负相关性 (r=-0.41,p=0.029).
结论:
- 甲托雷克萨特似乎没有影响RA患者的NAFLD或纤维化.
- 长期使用IL-6受体抑制剂可能与RA患者中NAFLD的减少有关.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
01:29Therapeutic Drug Monitoring: Affecting Factors
201
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
201
01:11Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
437
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
437
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185